940 Cediranib Affects Tumor Progression and Survival of Mice Bearing Human Ovarian Carcinoma Xenografts Expressing VEGFC von Decio, A, Cesca, M, Scarlato, V, Jurgensmeier, J.M, Taraboletti, G, Giavazzi, R, Belotti, D

Volltext

MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models von Furutani, S, Komaki, R, Smith, P.D, Jürgensmeier, J.M, Takahashi, O, Rabin, T, Herbst, R.S, O'Reilly, M.S

Volltext

700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC) von Loriot, Y., Balar, A.V., Petrylak, D.P., Rezazadeh, A., Grivas, P., Fléchon, A., Jain, R.K., Agarwal, N., Bupathi, M., Barthelemy, P., Beuzeboc, P., Palmbos, P., Kyriakopoulos, C., Pouessel, D., Sternberg, C.N., Pan, Y., Jürgensmeier, J.M., Goswami, T., Tagawa, S.T.

Volltext

46 POSTER VEGF receptor expression in human tumours: VEGFR-2 and -3 are confined predominantly to tumour vasculature von Smith, N.R, Baker, D.J, James, N.H, Ratcliffe, K.E, Ashton, S.E, Gray, N, Ryan, A.J, Jürgensmeier, J.M, Womack, C

Volltext

165 AZD2171, a potent VEGF receptor tyrosine kinase inhibitor, combined with mechanistically distinct antitumor therapies in vivo von Wedge, S., Kendrew, J., Valentine, P.J., Brave, S.R., Barnett, S., Jurgensmeier, J.M., Hennequin, L.F., Ogilvie, D.J.

Volltext

2659 von Imagumbai, T., Komaki, R., Milas, L., Valdecanas, D., Furutani, K., Ryan, A., Jürgensmeier, J.M., Ang, K.K., Herbst, R.S., O’Reilly, M.S.

Volltext

2659: Inhibition of VEGFR-1, -2, and -3 Signaling by AZD2171 Enhances the Anti-Tumor Efficacy of Radiation Therapy in a Mouse Xenograft Model von Imagumbai, T., Komaki, R., Milas, L., Valdecanas, D., Furutani, K., Ryan, A., Jürgensmeier, J.M., Ang, K.K., Herbst, R.S., O’Reilly, M.S.

Volltext